Lilly unites caring with discovery to create medicines that make life better for people around the world. We’ve been pioneering life-changing discoveries for nearly 150 years, and today our medicines help more than 47million people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world’s most significant health challenges, redefining diabetes care, treating obesity and curtailing its most devastating long-term effects, advancing the fight against Alzheimer’s disease, providing solutions to some of the most debilitating immune system disorders, and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we’re motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. R&D expenses before special items amounted to 5.3 billion euros. For more information, go to www.bayer.com
Biologix helps multinational pharmaceutical manufacturers bring innovative drugs to market in the MENA region. Positioned across 17+ key strategic locations in the GCC, Egypt, North Africa and the Levant, we are pioneers in regional distribution and promotion of innovative products and solutions for difficult-to-treat diseases.
A privately owned pharmaceutical company organized under the laws of UAE, Biologix provides end-to-end solutions from the preregistration phase all the way to commercial-scale market access and risk management including:
Incorporated in the Dubai Airport Free Zone in September 2002, Biologix traces its history back to 1997. We were among the first organizations to recognize the need for long-term strategic partnerships in the MENA region, and today we connect pharma leaders around the world with integrated direct-access healthcare approaches.
Biologix main partners include: Advanz Pharma, ALK, Alexion, BMS, Chiesi, Amgen...
Biologix premises are being regularly audited by the UAE Ministry of Health & Prevention and by its Principals and business partners. Furthermore, the company has acquired the ISO 9001:2015 Certification.
Merck is a leading science and technology company in healthcare, life science and performance materials. Around 50,000 employees work to further develop technologies that improve and enhance life – from biopharmaceutical therapies to treat cancer or multiple sclerosis, cutting-edge systems for scientific research and production, to liquid crystals for smartphones and LCD televisions.
Founded in 1668, Merck is the world’s oldest pharmaceutical and chemical company. The founding family remains the majority owner of the publicly listed corporate group. Merck, Darmstadt, Germany holds the global rights to the Merck name and brand. The only exceptions are the United States and Canada, where the company operates as EMD Serono, Millipore Sigma and EMD Performance Materials.
For more than a century, MSD, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for the world's most challenging diseases. MSD is a trade name of Merck & Co., Inc., with headquarters in Kenilworth, N.J., U.S.A. Through our prescription medicines, vaccines, biologic therapies and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching policies, programs and partnerships. Today, MSD continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
MSD products has been present for over 30 years in the GULF region through its local distributors in the UAE, Kuwait, Bahrain, Qatar & Oman and MSD ranks amongst the leading pharmaceutical companies in the region. MSD provides innovative medications in several therapeutic areas, including Anti-Infectives, Diabetes, HCV, HIV, Oncology and Anesthesia in addition to several specialized Vaccines.
For more information, visit www.msd.com and connect with us on Facebook, Linkedin, Youtube and Twitter at MSD GCC.
Pfizer is committed to providing shareholders, potential investors, and the public with a transparent view of our efforts toward fulfilling our purpose: Breakthroughs that change patients’ lives. To that end, our annual reports detail the strategic development, operations, and financial condition of our business. Hope Changes Lives.
We’re in relentless pursuit of scientific breakthroughs and revolutionary medicines that will create a healthier world for everyone.
Revolutionary medicines enable us to enrich and extend life for people living with all types of diseases.
This is our rallying cry as our scientists relentlessly pursue breakthroughs that will change patients’ lives.
We work tirelessly to translate advanced science and technologies into the therapies that matter most.
While we continue to see the devastating impact of the coronavirus pandemic around the world, we’re committed to helping keep people safe and informed.
Our ambitions are big and our product pipeline has never been stronger. We’re energized and inspired to apply science and our global resources to develop and deliver breakthrough therapies to people everywhere.
Founded to serve health, Servier is a global group governed by a Foundation that aspires to have a meaningful social impact, both for patients and for a sustainable world.With its unique governance model, it can fully serve its vocation with a long-term vision: being committed to therapeutic progress to serve patient needs. The 21,800 employees of the Group are committed to this shared vocation, source of inspiration every day.
As a world leader in cardiology, Servier's ambition is to become a renowned, focused and innovative player in oncology by targeting hard-to-treat cancers. That is why the Group allocates over 50% of its R&D budget to developing targeted and innovative therapies in oncology.
Neuroscience and immuno-inflammatory diseases are the future growth drivers. In these areas, Servier is focused on a limited number of diseases in which accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine.
To promote access to quality care for all at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, relying on strong brands in France, Eastern Europe, Brazil and Nigeria.
In all these areas, the Group includes the patient voice at each stage of the life cycle of a medicine.
Headquartered in France, Servier relies on a strong geographical footprint in over 150 countries and achieved a revenue of €4.7 billion in 2021.
More information on the new Group website: servier.com
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes through its Omnipod® product platform. The Omnipod DASH® Insulin Management System provides an alternative to traditional insulin delivery methods. With its simple, tubeless and waterproof* design, the single use Pod provides up to three days of continuous insulin delivery, without the need to see or handle a needle. For more information, please visit: www.insulet.com and www.omnipod.com.
*The Pod has a waterproof IP28 rating for up to 7.6 metres for 60 minutes. The PDM is not waterproof.
At Recordati Rare Diseases, we focus on the few - those affected by rare diseases. We believe that every single patient has the right to the best possible treatment. They are at the core of our thinking and our actions. Recordati Rare Diseases is a pharmaceutical company that provides treatment for patients with rare diseases. Created in 1990, Recordati Rare Diseases is one of the most active companies in the field of rare diseases. Our specialty rare disease products are marketed directly by Recordati Rare Diseases in Europe, the Middle East, the U.S.A., Canada, Russia, Japan and Australia, in some Latin American countries, and through selected partners in other parts of the world. Highly trained specialists and a scientific support team are available to collaborate with doctors, healthcare professionals, patients groups and families, to help improve the quality of life for people with rare diseases. Thanks to a unique production, packaging and distribution system developed for our products, our dedicated specialists are able to support patients in their home countries.
Recordati Rare Diseases is committed to supporting families affected by rare diseases through the research and development of new therapies and the distribution of specific scientific knowledge throughout the medical community.
EVA Pharma empowers the fight for health and well-being in communities around the world. With a 5,000-strong team of professionals, the company produces more than one million healthcare products a day at its state-of-the-art manufacturing facilities, which are equipped with cutting-edge technology, are internationally recognized for innovation, and have been approved by multiple regulatory agencies.
The company’s product portfolio focuses on pressing, yet unmet, disease areas, such as diabetes and cardiovascular diseases, oncology, neuroscience, ophthalmology, anti-infectives, bone and pain, hepatology, and reproductive health, to meet both local and international demand.
EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 40 countries worldwide.
For more information, please visit: www.evapharma.com & follow us on Facebook, LinkedIn & Instagram
At Ipsen, we’re dedicated to improving people’s lives and health outcomes. Our 5,000 employees around the world are committed to tackling areas of high unmet medical need to improve the quality of life of patients and caregivers.
LifeScan is a world leader in blood glucose monitoring – globally more than 20 million people depend on our iconic OneTouch® brand products to help them manage their diabetes.
Our vision is to create a world without limits for people with diabetes, their loved ones, and care teams.
For more than 40 years LifeScan has advanced glucose management and diabetes care with pioneering technologies and new products defined by simplicity, accuracy and trust.
From OneTouch® brand blood glucose meters, test strips, and lancets to an integrated digital health platform and hospital point-of-care systems, LifeScan is committed to offering patient-centric products and clinically-proven solutions.
Through partnerships with industry leaders, we will usher in the next wave of personalized health and wellness experiences that engage people with diabetes and related conditions to live their best lives.
